Morgan B P, Campbell A K, Compston D A
Lancet. 1984 Aug 4;2(8397):251-4. doi: 10.1016/s0140-6736(84)90298-8.
An immunoradiometric assay was used to measure the concentration of the terminal component of complement (C9) in cerebrospinal fluid (CSF) and plasma from 35 patients with multiple sclerosis and 55 controls with other neurological diseases. There was a highly significant reduction in cerebrospinal fluid C9 concentration in patients with multiple sclerosis (0.26 +/- 0.02 microgram/ml) compared with controls (1.52 +/- 0.20 micrograms/ml; p less than 0.0005). As a single protein measurement C9 seemed to be more useful as an aid to clinical diagnosis than CSF IgG; the C9 index was also a better discriminator than IgG index between the two groups of patients. Reduced CSF C9 concentration in patients with multiple sclerosis implies C9 consumption due to formation of membrane attack complexes, which could mediate myelin damage and cause more widespread but reversible loss of function, accounting for the transient symptoms characteristic of the disease.
采用免疫放射分析方法测定了35例多发性硬化症患者及55例患有其他神经系统疾病的对照者脑脊液（CSF）和血浆中补体终末成分（C9）的浓度。与对照组（1.52±0.20微克/毫升；p<0.0005）相比，多发性硬化症患者脑脊液C9浓度显著降低（0.26±0.02微克/毫升）。作为单一蛋白质测量指标，C9在辅助临床诊断方面似乎比脑脊液IgG更有用；C9指数在两组患者之间也是比IgG指数更好的鉴别指标。多发性硬化症患者脑脊液C9浓度降低意味着由于膜攻击复合物的形成导致C9消耗，这可能介导髓鞘损伤并引起更广泛但可逆的功能丧失，这解释了该疾病的短暂症状特征。
